MediWound Ltd. (MDWD)
MDWD trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1593984/000117891326000749/0001178913-26-000749-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MDWD on Nasdaq |
| Sector | Health Care |
| Industry | Medicinal Chemicals and Botanical Products |
| Country | Israel |
| IPO year | 2014 |
| SEC CIK | 0001593984 |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $17.0M |
| Net income | -$23.9M |
| Operating income | -$25.3M |
| Net margin | -140.8% |
| Operating margin | -149.0% |
| Revenue growth | -16.1% |
| Cash | $4.8M |
| Total assets | $86.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-05 |
| Cash and burn | $4.8M cash; operating cash flow -$4.0M a quarter. | Report 2025-12-31 |
| Shares outstanding | 12,835,148 (2025-12-31); 10,793,057 a year earlier; 7,240,020 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-11-05 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Somekh Chaikin, Tel Aviv, Israel | PCAOB Form AP 2026-03-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $143K, sold $82K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $17.0M | -$23.9M | -$16.1M | $4.8M | No debt tags | $17.0M | 20-F 2026-03-05 |
| FY 2024 2024-12-31 | $20.2M | -$30.2M | -$13.6M | $9.2M | No debt tags | $20.2M | 20-F 2026-03-05 |
| FY 2023 2023-12-31 | $18.7M | -$6.7M | -$10.5M | $11.9M | No debt tags | $18.7M | 20-F 2026-03-05 |
| FY 2022 2022-12-31 | $26.5M | -$19.6M | -$11.9M | $33.9M | No debt tags | $26.5M | 20-F 2025-03-19 |
| FY 2021 2021-12-31 | $23.8M | -$13.6M | -$8.9M | $11.0M | No debt tags | $23.8M | 20-F 2024-03-21 |
| FY 2020 2020-12-31 | $21.8M | -$9.2M | -$6.9M | $17.4M | No debt tags | $21.8M | 20-F 2023-03-16 |
| FY 2019 2019-12-31 | $31.8M | $5.0M | $8.3M | $7.2M | No debt tags | $31.8M | 20-F 2022-03-17 |
| FY 2018 2018-12-31 | $3.4M | -$1.1M | -$12.2M | $6.7M | No debt tags | $3.4M | 20-F 2021-02-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-05 |
| Latest annual report | 20-F | 2026-03-05 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 402 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.5% |
| 1 month | +5.6% |
| 3 months | -4.7% |
| Year to date | -30.1% |
| 1 year | -29.8% |
| From 52-week high | -33.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medicinal Chemicals and Botanical Products
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGC | Canopy Growth Corporation Common Shares | $0.5460 | -2.71% | $231.2M |
| NAGE | Niagen Bioscience Inc. | $2.01 | -2.66% | $159.2M |
| USNA | USANA Health Sciences Inc. | $13.54 | +2.27% | $250.3M |
| ACB | Aurora Cannabis Inc. Common Shares | $4.61 | -6.68% | $303.1M |
| SNDL | SNDL Inc. Common Shares | $1.34 | -2.19% | $326.0M |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $1.29 | +1.57% | $113.5M |
| TLRY | Tilray Brands Inc. Common Stock | $2.34 | -3.70% | $345.8M |
| ISPR | Ispire Technology Inc. | $1.52 | -10.06% | $87.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier